08:22 AM EDT, 10/14/2024 (MT Newswires) -- Jasper Therapeutics ( JSPR ) said Monday that preliminary data from its phase 1b/2a study of briquilimab showed that 93% of the adult participants with cold urticaria or symptomatic dermographism in both dose groups showed a clinical response to the treatment within six weeks.

In the 120mg dose cohort, 83% of participants experienced a complete response, the company said, adding briquilimab was well tolerated with no serious adverse events.

Jasper said that it secured regulatory clearance to enroll a 180mg dose cohort for the study and expects to report full trial data in the first half of 2025.

Shares of Jasper were up more than 15% in recent Monday premarket activity.

Price: 17.36, Change: +2.35, Percent Change: +15.66